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1. Introduction and aims 
Molecular recognition events are controlled by specific noncovalent interactions and they 
play key role in almost all biological processes[1-3]. Intermolecular contacts are affected by 
many different factors including shape and electrostatic complementarity of the molecular 
surfaces[4, 5]. Focusing on protein–protein complexes, the free energy of the binding is directly 
related to the buried mostly flat surface area, which lacks deep binding pockets shielded from 
water. These interactions are therefore coined “undruggable” for a small-molecule drug 
candidate[6, 7]. In order to modulate the function of such protein complexes, extended molecular 
surface mimetics are required with a specific arrangement of the hot-spot residues[8-11]. This can 
be achieved by synthesizing rigid scaffolds via introducing cyclic constraints into the 
molecules; thus, the interacting surface is a direct product of the chemical synthesis[12, 13]. The 
well-defined shape of the molecule can be created in a subsequent stage through a folding 
procedure depending on the solution conditions and interacting partners. Typically, 
biopolymers and their structural mimetics can self-organize into these kinds of hierarchical 
structures. In terms of molecular recognition, foldamers, i.e., non-natural oligomers with 
distinct conformational preferences, are interesting, due to their ability to mimic structure and 
functions of biopolymers[14-16]. Predictable three-dimensional structures can be generated from 
monomeric modules leading to large exposed surface patches, which make foldamers attractive 
tools for high-affinity, specific recognition of protein interfaces[17, 18]. Although ribosomal 
incorporation of foldameric building blocks has been achieved in special cases[19], foldamers 
are fundamentally evolution-free chemical entities. De novo or bottom-up design strategies are 
therefore particularly difficult for foldamer sequences in cases, where limited structural 
information is available about the target surface. 
Our main goal was to design foldameric binders for the recognition of difficult protein target 
surfaces[6] by applying bottom-up design approaches. One of our molecular targets was the 
soluble β-amyloid oligomer[20-23]. Its level in cerebrospinal fluid correlates with the cognitive 
impairment in Alzheimer’s disease, which makes it an attractive biomarker for monitoring the 
progression of the disorder[24, 25]. Application of the foldamer methodology and the fragment-
based approach resulted in the development of high-affinity interacting partner for β-amyloid. 
Therefore, by exploiting this interaction, the aim was to optimize a sandwich-type affinity assay 
using multivalent foldamer conjugate as a capture antibody mimetic. In order to develop a 
specific and selective assay, structural optimization of the capture molecule and increasing the 
efficiency of the detection system were necessary. 
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As another target, a model protein calmodulin having two separate hot-spot pockets[26, 27] 
was chosen for modular bottom-up design of a foldameric inhibitor. In order to find weakly 
interacting partners of the protein, a surface-patch mimetic library containing short foldameric 
fragments was screened and the simultaneous optimization of the two binding hot spot 
fragments was achieved by ligating the hits via dynamic combinatorial chemistry[28]. 
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2. Literature background 
2.1. Characterization of protein interfaces 
Molecular recognition is fundamentally determined by the free energy of binding[1, 2]. 
Investigation of host–guest complexation provides deeper insight into protein functions and 
elementary processes of biological systems. Although protein–protein interactions (PPIs) have 
promising therapeutic potential[29-31], protein surfaces are difficult to recognize with synthetic 
molecules[11]. The main reason is that protein interfaces, through which the direct physical 
contact occurs, are usually large and shaped irregularly requiring extended molecules for 
selective, high-affinity interaction[32]. There are a number of factors, which characterize these 
seemingly featureless surfaces such as electronic properties (charge, polarity, polarisability, van 
der Waals attraction and repulsion), size, shape, number, and arrangement of the binding sites 
on the interfaces[5]. 
2.1.1. Buried surface area and hot-spot residues 
The interaction interfaces have relatively large complementary surface areas, which vary in 
the range 1500–3000 Å2[4, 33]. Compared with the average contact area between a small ligand 
and a receptor (300–1000 Å2), the former values are considerably larger. Consequently, a high-
molecular weight PPI inhibitor is required to meet challenges associated with the free-energy 
contributions scattered over the extended contact surfaces. Hydrophobic interaction is the main 
driving force for PPIs[34], and electrostatic complementarity interactions, i.e., hydrogen bonds 
and salt bridges also stabilize protein complexes[35, 36]. Interfaces are fundamentally modular 
and the key stabilizing interactions are not homogeneously distributed. Residue mutations to 
Ala causing a significant change in the binding free energy (at least 2 kcal mol-1) are defined as 
hot-spot residues[10, 37], and these contribute dominantly to the stability of the protein–protein 
complexes. These special modules are structurally conserved and alanine scanning studies 
indicate distinctive amino acid compositions[8, 37-39]. If the total interaction surface is under 2000 
Å2, it is usually composed of a single patch, whereas larger contact surfaces are created by 
separate hot-spot patches surrounded by solvent-exposed regions leading to a discontinuous 
epitope[38]. 
2.1.2. Classification of protein–protein interactions 
On the basis of common structural elements and the modes of interaction, protein–protein 
complexes can be classified into four main categories[4], which fundamentally define the 
druggability of the interactions[6, 11] (Figure 1). „Tight and narrow” interactions are the most 
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similar to the classical receptor–ligand model and, therefore, these PPIs have proven to be the 
most amenable to inhibition. This kind of interaction occurs, for example, between interleukin 
2 (IL-2) and IL-2α receptor[40], mouse double minute 2 (MDM2) and p53 tumor suppressor 
protein[41], and between the anti-apoptotic Bcl-2 family members and BH3 domain of pro-
apoptotic BAK/BAX[42]. There is a rich literature with respect to successful development of 
small-molecule PPI inhibitors. In these cases, the hot-spot residues usually group within a 
tightly packed cluster, typically in a binding cleft for α-helix recognition on the surface of a 
globular protein[6, 43]. In contrast, PPIs within category „Loose and Narrow” are formed through 
relatively small contact areas, and the shallow binding pocket allows just a weak interaction 
making them difficult to target. They are usually transient complexes and there are only a few 
examples of their successful inhibition[44, 45]. “Loose and Wide” interactions are the most 
extremist cases of the PPIs, characterized by large interacting surfaces and micromolar 
affinities. The Ras/SOS (Son of Sevenless) complex is one of the few examples of PPIs 
belonging to this category and it was successfully inhibited with small-molecule ligands[46]. The 
most challenging task is probably the disruption of globular protein complexes belonging to 
category „Tight and Wide”. In these PPIs, the recognition of a relatively large and flat surface 
is required[47] with frequent involvement of convoluted or discontinuous interaction surfaces 
(Figure 1). The most potent inhibitors are extended molecular surface mimetics that can provide 
specific arrangement of the desired hot-spot residues. 
 
Figure 1. Classification of protein–protein interactions (PPIs) on the basis of the buried surface area and 
the binding affinity. Narrow interacting surfaces require small-molecule inhibitors, while protein 
complexes rely on wide contact areas usually requiring extended surface mimetics. 
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2.2. Targeting protein recognition surfaces 
Targeting a large solvent-exposed protein interface requires inhibitors with comparable 
surface area, which can compete successfully for separate hot-spot binding sites. In inhibitor 
design, precise projection of the multiple anchor points is crucial for high-affinity binding[32, 
48]. Beside antibodies, which are still the gold standards for high-affinity recognition, there are 
two main strategies to create distinct molecular shapes: multivalent presentation of recognition 
domains on a rigid supramolecular scaffold or formation of a well-defined molecular surface in 
a subsequent folding process.  
2.2.1. Antibody mimetics 
Despite the poor pharmacokinetic properties, immunogenicity, and costly time-consuming 
production, antibodies are still the most efficient tools for selective, high-affinity molecular 
recognition. To overcome their limitations, there is a growing interest in artificial antibody 
mimetics. They are functional mimetics of antibodies having tailored characteristics but 
retained low nanomolar binding affinity toward antigens[49, 50]. On the basis of the originating 
proteins, we can distinguish different types of these engineered scaffolds, such as affibodies, 
adnectins, affimers, anticalins, fynomers, knottins, DARPins, etc. Some of them already have 
remarkable importance as diagnostics and in therapeutic applications[51-53]. 
2.2.2. Protein surface mimetics 
An obvious solution to extend the surface of a small molecule is linking together multiple 
copies, where multivalency increases the binding affinity of a given ligand. Positioning the 
multiple recognition elements on a suitable rigid scaffold results in multivalent non-covalent 
contacts over a large area of protein surface. Rigid scaffolds like anthracenes, calixarenes, 
porphyrins, cyclodextrins, and resorcinarenes ensure direct coordinative interactions and 
selective binding of higher affinity can be achieved[54-57]. 
2.2.3. Peptide-based protein–protein interaction inhibitors 
Peptides, because of their low conformational and proteolytic stability, are normally not 
preferred as drug candidates. Nevertheless, they are promising starting materials to develop PPI 
inhibitors. Increasing the stability of the active conformation could increase the binding affinity 
to the target and, at the same time, decrease the possibility of degradation. These are mainly 
secondary structure mimetics, where two strategies available for their production are the 
rigidification of the molecule via cyclization and the modification of the backbone to increase 
protease resistance (Figure 2)[13, 48]. 
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Figure 2. Structural modification possibilities to create peptide-based inhibitors with improved 
conformational and proteolytic stability: a) stapled peptide resulting from cyclization (pdb: 2YJA), HBS 
(hydrogen bond surrogate, pdb: 4MZL), β-hairpin (pdb: 2AXI), and miniprotein (pdb: 3IUX); b) 
backbone modifications. 
Cyclopeptides can mimic native protein structures while exhibiting enhanced metabolic 
stability[12]. The structural preorganization limits their conformational flexibility and reduces 
the entropic cost of binding. Cyclization can be performed by covalent coupling of the C- and 
the N-terminal end of the peptide sequence (head-to-tail) to stabilize the active conformation of 
the native ligand[58]. Joining side chains by covalent bonds, which are in spatial proximity in 
the desired conformation, results in stapled peptides (Figure 2a). Usually, i, i+4 or i, i+7 
hydrocarbon staples are formed to stabilize α-helical structure[59, 60]. Very often, however, these 
crosslinks cause additional hydrophobic interactions and lower solubility, which alter both the 
recognition properties and the selectivity of the stapled form[61]. The hydrogen bond surrogate 
(HBS) strategy is also based on the formation of a peptide macrocycle, where an i to i+4 
backbone hydrogen bond is replaced by a carbon–carbon bond[62, 63] (Figure 2a). The crosslinker 
of an HBS ligand is less exposed to the enviroment relative to the stapled helix crosslinks, and 
the side-chain functionality is retained. Protein-binding peptidic epitopes can be incorporated 
into a semi-rigid macrocycle with a turn-inducing unit (Figure 2a). Such β-hairpin 
peptidomimetics are composed of two consecutive H-bonded antiparallel β-strands, where the 
size of the hairpin loop is a variable parameter[64]. Another interesting scaffold to graft the 
identified binding epitopes are miniproteins, namely, oligopeptides with three-dimensional 
structure stabilized by disulfide moiety[65] (Figure 2a). The well-defined, stable folded structure 
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ensures the specific arrangement of the side chains of the epitope sequence and stabilizes the 
linear peptide binders, which can improve the binding affinity of the peptidic ligands. 
Backbone modified peptidomimetics with improved proteolytic and conformational stability 
are other promising alternatives to peptidic analogs. The major possibilities are i) the use of D-
analogs of the natural L-amino acids, ii) substitution of some or all amino acids to β-homologs, 
iii) repositioning the proteinogenic side chains to the peptide bond nitrogen atom by using 
peptoid as a scaffold (Figure 2b). Replacement of the L-amino acids to D-amino acids is a well-
known strategy to develop peptide-based bioactive compounds, that significantly reduce the 
possibility of proteolytic degradation[66, 67]. Although retro-inverso isomerization allows similar 
side chain topology as its parent molecule with inverted amide peptide bonds, sometimes it 
works poorly in molecular mimicry of biologically active helices[68]. Despite the similar side-
chain topology, it is not equivalent with the L-analogs at the secondary structure level, and the 
binding mode for the D-variant fragments usually differs from the native ligand. β-Peptides are 
oligomers containing β-amino acids exclusively or in combination with α-amino acids. As they 
have a high tendency to form stable conformations in solution, these molecules are referred to 
as β-peptide foldamers and they are discussed in details in the next section. Peptoids are N-
substituted oligo-glycines belonging to the family of peptidomimetic foldamers due to their 
structural similarities[69, 70]. The nitrogen of the peptide bond contains the side chain and, 
therefore, it loses the ability to serve as a hydrogen donor and, therefore, peptoids require 
fundamentally different stabilization of the secodary structure. The lack of stabilizing backbone 
H-bonds makes the peptoids highly flexible and, therefore, the de novo design of well-defined 
secondary structures is challenging. Nevertheless, they are still attractive scaffolds for 
biomedical applications[69, 71]. 
2.3. β-Peptide foldamers 
β-Peptides are the most extensively studied subset of foldamers, i.e., they are self-organizing 
synthetic oligomers with high propensity to form well-defined structural elements[72, 73]. The β-
peptide foldamers are programmable structural and functional mimetics of biopolymers, which 
makes them promising alternatives for biopharmaceuticals[16]. Introducing unnatural β-amino 
acids into the α-peptide backbone significantly increases the proteolytic stability of the 
peptide[74, 75]. Even when the chain lengths are as short as five or six residues, they are able to 
fold into distinct secondary structures (helices, turns, and strands) that can exhibit similar 
interaction surfaces to larger proteins, which is particularly advantageous for protein surface 
recognition[32, 48, 76]. 
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2.3.1. Building blocks and secondary structures 
The difference between β- and α-amino acids is that the former is elongated with one 
methylene (Cβ) in the backbone. Furthermore, due to the additional substitution position and 
stereogenic center, the β-amino acid building blocks are characterized by higher diversity 
(Figure 3). Depending on the substitution pattern of the monomers we can distinguish β2-, β3-, 
and β2,3-amino acids and their syntheses are performed in different ways[77]. For β2-amino acids, 
the overall enantioselective Mannich reaction or Curtius degradation is applied. The β3 building 
blocks are obtained by Arndt–Eistert homologation of α-amino acids[78, 79], and they are now 
commercially available with a few exceptions (β3hHis, β3hCys, β3hSec)[80]. The β2,3-amino 
acids are prepared from the appropriate β3-amino acids by enolate alkylation. Both the Cα and 
Cβ atoms can be in a cycloalkane or a heterocyclic ring, which decreases the conformational 
flexibility and stabilizes a given secondary structure[81]. Beside pure β- peptides, α/β-peptide 
foldamers can be synthesized by introducing β-amino acids into the α-peptide chain in 
appropriate combination (ααβ, αααβ, ααβαααβ) to ensure substantial protection from 
degradation but retain α-helical conformation[82]. 
 
Figure 3. Structural diversity of β-peptide foldamers: a) monomeric modules with additional 
substitution position and cyclic derivatives, b) side and top views of a 14-helix of a pure β-peptide. 
From molecular recognition point of view, the predictable structures of the β-peptides are 
particularly advantageous, and the diverse secondary structures give us a useful toolbox for 
inhibitor design. Similar to α-peptides, the secondary structures are stabilized by hydrogen 
bonds and the folding depends on local conformational preferences and long-range hydrophobic 
interactions. The β-amino acid units having specific stereochemical configuration and 
stereochemistry not only define the primary sequence of the peptide, but its secondary structure 
is also predictable from the sequence of monomers. The stereochemical pattern of the backbone 
encodes the folding propensity of the molecule: if the signs of the torsions flanking the amide 
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moiety are the same, a helical conformation will be formed whereas if they are opposite, then a 
strand is induced[17]. The whole palette of β-peptide secondary structures is diverse containing 
helices with different inner diameter, turns, and strands. Folding behaviours of these oligomers 
are multifactorial, and several different helix and strand conformations have been 
experimentally observed such as 8-, 10-, 10/12-, 12-, 14-, 14/16-, 18-, 18/20-helices, extended 
polar, Z6 non-polar, and alternating polar strands[83-85]. Beside the stereochemical pattern of the 
backbone, the folded shape of the molecule is affected by i) the chain length of the oligomer, 
ii) the bulkiness of the monomeric units, iii) the amount of the dihedral constraints in the 
sequence, and iv) solution conditions. Application of an α/β heterogeneous backbone can 
further increase the diversity, depending on the α/β ratio and their pattern, unique helical 
structures such as 14/15-, 11-, 9/10/11/12-helices can be induced[86, 87]. 
The predictable folding behaviour and improved proteolytic stability makes the class of 
foldamers a promising candidate for protein surface recognition. Several proteins have already 
been targeted with foldamers, such as Bcl-xL-BAK, hDM2-p53, VEGF-VEGFR1 complexes[18, 
88-91], somatostatin, parathormon, and GLP-1 receptors[92-94]. 
2.3.2. Bottom-up design approaches for molecular recognition 
The development of complex molecular building blocks having controllable morphologies 
and functionalities is required for the interaction with biological interfaces. While extensive 
knowledge of the structure of the interacting partner is needed for top-down design, bottom-up 
design strategies require the ability to de novo build-up molecules in a highly controlled 
manner. Top-down approaches are frequently used for foldamers and other peptidomimetics[82, 
95], but limited structural information about the target or the lack of known peptidic binder 
makes the ligand design more challenging. Despite the fact that foldamers are able to make 
predictable three-dimensional structures thus providing specific arrangement of the 
proteinogenic side chains, there are only a few examples to create a foldameric ligand by using 
de novo bottom-up approaches. 
Fragment-based methods are iterative small-to-large molecule strategies. The iterative 
process consists of at least two main steps: i) a fragment screening, during which weakly-
binding (KD=0.1–10 mM) low-molecular mass fragments are identified, ii) a fragment 
elaboration with merging, linking or growing to develop more potent compounds of larger 
molecular weight[96]. Although it is frequently used in small-molecule drug candidate[97], this 
method is not used among foldamers with some notable exceptions[98, 99].  
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Another versatile tool to find high-affinity protein binders is high-throughput screening 
(HTS) of large libraries of compounds. In larger libraries (up to 106) the compounds are usually 
simplified, not druglike molecules. However, if we increase the complexity of the members 
with the necessary size reduction of the library, only a small fraction of possible chemical space 
can be investigated. Therefore, further optimization of the hits is required in every case. 
2.3.3. Dynamic combinatorial chemistry 
Conventional drug discovery methods are slow and expensive, because the technology 
consists of iterative cycles of design–synthesis–screening. There is therefore a growing interest 
in using directed evolution methods for reliable optimization of protein binders[100]. When 
mimicking the natural evolution process in vitro, the synthesis and screening of large libraries 
occur simultaneously. Since unnatural foldamers are fundamentally evolution-free chemical 
entities, in vitro evolution methods are not applicable for the optimization of their structure, but 
dynamic combinatorial chemistry (DCC) can be an alternative for designing functional 
materials[101]. Dynamic combinatorial libraries (DCLs) rely on the reversible generation of 
compound mixtures under thermodynamic control, where the overall system can adapt to 
external stimuli such as addition of a protein template by shifting the dynamic equilibrium 
towards the formation of the tightly binding ligands[102, 103]. Driven by thermodynamic control, 
the final product distribution is formed on the basis of the position of different compounds in 
the free-energy landscape, which eventually causes the main limitations of the methods[104]. In 
DCL experiments, the template concentration and the size of the library are the most crucial 
parameters. To the introduction of a target protein, DCLs respond in a way to minimize the free 
energy of the entire system. Small, but weaker binders are preferred over larger, but strong 
binders, because the overall entropic penalty is usually high in the latter case. Furthermore, a 
large number of weak binders successfully compete with the few strong binders[105]. At high 
template concentration, these unwanted phenomena are even more pronounced, because the 
large amount of template does not restrict the number of binding sites. In this case, the overall 
amplification of the library members is significantly increased, which is advantageous for 
analysis, but the selectivity is drastically decreased[106]. Detailed calculations show that 
application of about 0.1 equivalent of template even in larger libraries results in a good 
correlation between amplification and binding[106]. Investigation of larger libraries provides 
higher probability of identifying the best binder, because the affinity of the detected members 
increases with the increasing library size[104]. Due to simple probability, the formation of 
homomeric library members is less preferred over that of heteromeric ones. If a homo-oligomer 
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is still a good binder, its amplification indirectly upregulates other library members devoid of 
the corresponding building block[107]. This co-amplification may further decrease the 
probability to find real good binders. Taking these into account, finding the best binder in this 
way means drawing correct conclusions from really complex response of DCLs to molecular 
recognition events, that requires careful design of the buliding blocks, experiments, and 
analyses. 
2.4. Targeting β-amyloid oligomers 
2.4.1. Alzheimer’s disease and β-amyloid peptide 
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorder[108]. 
Although the cause of the disease is poorly understood, its progression is in close relation to β-
amyloid peptides, the cleavage products of amyloid precursor protein (APP)[25, 109]. The primary 
products of secretases are β-amyloid peptides with lengths of 40 and 42 amino acids (Aβ40 and 
Aβ42). Studies confirmed that the longer-sequence Aβ42 shows higher aggregation 
propensity[110], and it is more toxic to neuronal cells. It has also been shown previously, that the 
mostly disordered Aβ42 monomer has a neuroprotective effect on neuronal cell culture[111], but 
the peptide can rapidly form structured monomer (β-hairpin) and associates to create oligomers, 
protofibrils, and fibrils depending on the conditions (peptide concentration, pH, temperature, 
salt concentration, etc.). Despite the fact that physiological effects of these associated species 
are intensely studied, their direct connections to different states and the progression of AD are 
still not fully understood. Several pieces of evidence prove that soluble Aβ42 oligomers are the 
most neurotoxic assemblies. They drive the degenerative pathology of AD, and their amount in 
the cerebrospinal fluid shows correlation with cognitive decline[20, 112]. Therefore, the Aβ42 
oligomer can serve not only as a therapeutic target but also as a potential biomarker to monitor 
the progression of the disease. The structure of the amyloid fibril is now well-characterized[113] 
in contrast to neurotoxic Aβ42 oligomers. The structural polymorphism and sample 
heterogenity make the high-resolution structure of the oligomer difficult to study[114]. In the 
aggregation pathway of amyloid, monomers can form oligomers of low and high molecular 
weight (LMW and HMW). Both oligomers are disc-shaped with diameters of about 10–15 
nm[21, 115]. Within the oligomer, the N-terminal ends (residues 1–13) of the monomeric units are 
disordered with high flexiblity. The middle part of the peptide (residues 14–23) is the self-
recognition region, which is responsible for the lateral association of the unstructured oligomers 
and β-sheet formation. The C-terminal ends create the hydrophobic core of the oligomer and 
mediate fibril formation by stabilizing the cross β-sheet structure. The solvent-exposed 
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hydrophobic patch in the middle part of the sequence K16LVFFAE22 (Figure 4) is identified as 
an intermolecular contact during oligomerization and most of the small-molecule and peptidic 
inhibitors target this part of the Aβ aggregates[116]. 
 
Figure 4. Top and side view of the high-resolution structure of monomorphic Aβ fibrils[117] (pdb: 
5KK3). The solvent-exposed K16LVFFAE22 sequence is highlighted. 
2.4.2. Sensitive detection of β-amyloid 
On the basis of strong belief in the amyloid cascade hypothesis[109], many AD drug 
developments focus on targeting the production, fibrillation, and clearance of Aβ. The possible 
reason for Aβ-related treatment strategies failing at clinical studies is that the pathogenesis of 
AD is multifactorial. Consequently, for effective therapy, early detection before the start of the 
irreversible neurodegeneative processes would be essential[118]. Sensitive quantification of the 
potential biomarker Aβ oligomer may be suitable for early diagnosis of the disorder and for 
monitoring the effect of different anti-AD treatments. It is especially important in those stages, 
where the asymptomatic nature of the disease makes the diagnosis difficult. Current diagnostic 
methods are mostly based on imaging of Alzhemer’s disease plaques in the brain in the later 
stage of the disorder[119]. In parallel, many strategies based on nanotechnology and 
biotechnology have been published for reliable detection of soluble Aβ aggregates (Table 1). 
The detection methods are mostly relied on high-affinity interactions between specific 
antibodies (capture elements) and different types of Aβ associates with very impressive 
picomolar limit of detection. 
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Table 1. Summary of strategies for early detection of AD. 
Capture elements Targets Application 
Limit of 
detection* 
mAb158, monoclonal Ab 
Aβ42 protofibrils in 
CSF 
sandwich ELISA[120] 1 pmol/L 
BAN50, N-terminal (1–16) 
specific monoclonal Ab 
HMW oligomers of 
Aβ42 in CSF 
sandwich ELISA[121] 10 pmol/L 
mAb4G8, sequence specific 
monoclonal Ab and fluorescence 
labeled mAb6E10 
different Aβ42 
aggregates 
in CSF 
surface FIDA[122, 123] nd 
ASR1, hexamer peptoid 
conjugated to bead  
Aβ 40/42 oligomers in 
CSF 
MPA; Capping Aβ 
oligomers prior to 
ELISA detection[124] 
1 pmol/L** 
MMPs and oligonucleotide-
modified Au NPs functionalized 
by Abs 
ADDL in CSF Bio- barcode assay[125] 0.0001 pmol/L 
Silver NPs functionalized with 
anti-ADDL Ab 
ADDL in CSF LSPR nanosensor[126]  <10 pmol/L 
mAb158, monoclonal Ab 
Aβ42 protofibrils in 
CSF 
SP-PLA[127] 0.01 pmol/L*** 
PrPC immobilized on gold 
electrode, ALP conjugated PrPC 
soluble Aβ42 oligomer 
ALP-based biosensor 
supplemented with ECC 
redox cycling[128] 
3 pmol/L 
Fluorescent labeled sequence 
specific Abs (6E10- 4G8) 
soluble Aβ42 oligomer 
FRET-based flow 
cytometric analysis[129, 
130] 
<1 pmol/L 
A11 and OC conformation 
specific Abs on the surface of a 
silver electrode 
soluble Aβ42 oligomer EIS[131] nd 
Ab: antibody, ELISA: enzyme-linked immunosorbent assay, HMW: high molecular weight, MPA: 
Misfolded Protein Assay, FIDA: fluorescence intensity distribution analysis, MMP: magnetic 
microparticle, NP: nanoparticle, ADDL: amyloid beta-derived diffusible ligands, LSPR: localized 
surface plasmon resonance, SP-PLA: solid-phase proximity ligation assay, PrPC: cellular prion protein 
(95–110), ALP: alkaline phosphatase; ECC: “outersphere to inner-sphere” electrochemical–chemical–
chemical, FRET: fluorescence resonance energy transfer, EIS: electrochemical impedance spectroscopy 
*relative to monomer concentration 
** defined as 80 fM oligomer, where the average composition of one oligomer is 12 monomers 
*** expressed in 0.04 pg mL-1, regarding the MW of Aβ is 4.5kDa  
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3. Experimental methods 
3.1. Synthesis and purification of peptides and conjugates 
Peptides and maleimido-functionalized oligo-L-lysin-dendron scaffolds were synthesized 
manually by SPPS, according to the Fmoc/tBu strategy using Tentagel R RAM resin (capacity: 
0.19 mmol g-1) and Rink Amide AM resin (0.30 mmol g-1). The Fmoc-protecting groups were 
removed by using 2% piperidine and 2% 1,8-diazabicycloundec-7-ene (DBU) in N,N-
dimethylformamide (DMF) (5+15 minutes). Washing procedures were carried out with DMF, 
dichloromethane (DCM), and methanol. Peptide chain elongation was done by activating a 
three-fold excess of N-Fmoc protected amino acids with 1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]-pyridinium-3-oxide hexafluorophosphate (HATU)/N,N-
diisopropylethylamine (DIEA) in DMF for 3 hours. Efficiency of the coupling steps was 
monitored with the Kaiser test. The peptides were cleaved from the resin with a mixture of 
trifluoroacetic acid (TFA)/H2O/1,4-dithiotreitol (DTT)/triisopropylsilane (TIS) (90:5:2.5:2.5) 
at room temperature for 3 hours. Coupling of 3-maleimidopropionic acid (MPA) to the N-
terminal of the lysine dendrons was also carried out on the solid support and peptides were 
cleaved from the resin with a cleavage mixture of TFA/H2O/TIS (92/5/3). TFA was evaporated 
and the peptide was precipitated in dried diethyl ether. The resulting free peptide precipitate 
was filtered off, dissolved in 10% aqueous acetic acid or in the mixture of acetonitrile/H2O, and 
lyophilized. 
Maleimide-thiol ligation. The purified and lyophilized maleimido-functionalized scaffolds 
were dissolved in 50 mM phosphate buffer (pH = 7.0) and added dropwise to the solution of 
1.3 × N equivalent of peptide-thiol dissolved in the same buffer under constant stirring (N is 
the number of arms of the conjugate). The reaction mixture was stirred overnight at room 
temperature and then injected directly onto a semi-preparative reverse-phase (RP) HPLC 
column and for purification. 
Synthesis of the foldamer fragment libraries. For the synthesis of foldamer libraries a 
CEM Liberty 1 microwave peptide synthesizer was used with the amino acids added manually. 
Rink Amide PS resin was used for solid support and HATU as a coupling reagent. (1S,2S)-
Fmoc-2-aminocyclohexane carboxylic acid [Fmoc-(1S,2S)-ACHC] was applied in an excess of 
3 equivalents at 75 °C for 30 minutes. β3-Amino acid mixtures were double coupled using 0.8 
equivalents at 75 °C for 45 minutes. 16 different β3-amino acids were coupled in position 5 of 
the sequence and 4 different amino acids in the position 4, which yielded 64 different 
components in each sublibrary. Deprotection was carried out in a solvent mixture of 2% 
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piperidine and 2% DBU in DMF for 10 minutes at 75 °C. The foldamer mixture was cleaved 
by 90% TFA, 5% DTT, 5% water, then TFA was evaporated and the resin washed with acetic 
acid and water. Finally, the product mixture was lyophilized. 
Purification. Peptides and conjugates – based on the amount of the crude product – were 
purified on a semi-preparative (250 × 10.00 mm) or on a preparative (250 × 21.2 mm) RP-
HPLC column. According to the hydrophobicity and the size of the molecules, Phenomenex 
Luna (particle size: 10 µm, pore size:100 Å) C18 or Jupiter (particle size: 10 µm, pore size: 300 
Å) C4 or C18 was used with the appropriate gradient elution using the following eluents: (A) 
0.1% TFA in water and (B) 0.1% TFA in ACN/water (80/20). Peptide purity, confirmed by 
analitical RP-HPLC and ESI-MS measurements, was above 95% for all compounds. The 
foldamer libraries were purified by using a steep gradient (0–90% during 90 minutes with the 
flow rate: 4 mL min-1), then fractions were analyzed by MS and each fraction that contained 
library members was pooled together. Library components were identified by HPLC-MS based 
on molecular weight and retention time estimated by hydrophobic properties of the peptides. 
Purity analysis was based on quantification of the total library members and impurities by 
integration of the HPLC-MS chromatograms. 
3.2. Preparation of β-amyloid samples 
For the binding studies, Ser26 depsipeptide iso-Aβ (1–42) was used, which was synthesized 
and purified as described previously[132]. The lyophilized iso-Aβ (1–42) was dissolved in MilliQ 
water in a concentration of 1 mg mL-1, sonicated for 3 minutes and the pH was set to 7.0 to 
initiate an O to N acyl migration, whereby the native sequence can be readily formed. The 
sample was incubated at room temperature for 10 minutes. Then the pH was set to 11 and the 
sample was kept at room temperature for additional 2 hours. After the incubation, the Aβ stock 
solution was aliquoted and stored at –20 °C until use. To obtain Aβ oligomers, the aliquot of 1 
mg mL-1 was diluted to a final concentration of 50 μM with 26.67 mM PBS and the pH was set 
to 7.4 with 1 M HCl. The sample was incubated at 37 °C for 3 hours. To calculate the accurate 
concentration of the Aβ solution, the peptide content of the lyophilized iso-Aβ (1–42) was 
determined by amino acid analysis, and it varied typically between 70–80%. Exact peptide 
concentrations of the stock solution were calculated by taking these data in consideration. 
3.3. ELISA experiments 
PIERCE (Rockford, IL, USA) avidin (125 pmol/well or 60 pmol/well) coated plates were 
used for the ELISA experiments. The capture molecule was dissolved in phosphate buffer saline 
(PBS) at a concentration of 10 mg ml-1, and 100 µl capture molecule solution was pipetted in 
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each well and incubated for 2 hours at room temperature. The plate washed three times with 
200 µl TPBS [20 mM PBS containing 1% bovine serum albumin (BSA) and 0.1% TWEEN20] 
was incubated with 100 µl diluted amyloid solution under shaking (overnight, 4 °C). After 
washing the plate three times with 200 µl TPBS, the primary antibody (6E10, Covance, Leeds, 
UK) was diluted with the washing buffer (1:10000 dilution) and 100 µl diluted primary 
antibody solution was pipetted into each well. The sample was incubated for 1 hour at room 
temperature. The plate was washed three times with 200 µl TPBS and 100 µl of the secondary 
antibody Histols-M (Histopathology Ltd., Pécs, Hungary) in 1:250 dilution or anti-mouse IgG 
HRP (Dako, Glostrup, Denmark, 1:10000 dilution) was pipetted to each well. After 1-hour 
incubation at room temperature, the plate was washed twice with 200 µl TPBS (in the first 
washing step the TPBS solution was left in the plate for 30 minutes). Development was carried 
out with 100 µl 3,3',5,5'-tetramethylbenzidine (TMB) solution pipetted into each well and the 
absorbance was measured with a plate reader (NOVOstar OPTIMA, BMG Labtech, Offenburg, 
Germany) in plate mode, for approximately 1.5 hours. For validation, Innotest® β-amyloid (1–
42) (Innogenetics, Gent, Belgium) assay was performed according to the manufacturer's 
instructions. 
3.4. ITC experiments 
Isothermal calorimetric titrations were performed with a Microcal VP-ITC microcalorimeter 
in pH 7.4 PBS buffer solution. In individual titrations, 10 µL portions of the solution containing 
the ligand were repeatedly injected from the computer-controlled 300-µL microsyringe at 
intervals of 300 s into the Aβ oligomer solution prepared in the same buffer as the ligand. All 
measurements were carried out at 285 K. The Aβ concentration in the cell was 100 µM and the 
total ligand concentration was 250 µM in the syringe. The titration was stopped when the 
precipitation of the Aβ aggregates became excessive. 
For ITC analysis of the CaM–foldamer interaction, 20 mM HEPES with 30 mM CaCl2, pH 
7.0 was used as a buffer. Peptide solutions were sonicated for 20 minutes before titration to 
avoid aggregation. The foldamer solution (10 or 15 μl) was injected from the computer-
controlled microsyringe into the CaM solution at intervals of 240 s. The CaM concentration in 
the cell was between 3 and 7 μM, and the concentration of foldamers in the syringe was 85–
200 µM. The temperature was adjusted to 298 K. Control experiments were performed by 
injecting the ligand into a cell containing buffer with no target, and the heats of dilution were 
subtracted from those measured in the presence of the protein. The experimental data were fitted 
to the two independent binding site model by using a nonlinear least-squares procedure, with 
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ΔHb, ΔHb’, Kd, Kd’ (dissociation constants), n and n’ (number of binding sites for monomer), as 
adjustable parameters. 
3.5. Pulldown assay 
Screening of the folded fragment library with CaM was carried out by pulldown assay. 100 
µl of 50 w/v% cobalt affinity resin suspension (TALON, Takara Bio USA, Inc., Mountain 
View, CA) was pipetted into a paper filter spin cup (Thermo Scientific), centrifuged at 1000 
RPM for 2 minutes, and washed three times with 300 µl of 20 mM HEPES buffer (pH 7.4), 
which contained 150 mM NaCl and 1 mM CaCl2. Polyhistidine-tagged CaM was conjugated to 
the resin at a 2 mg ml-1 concentration, and the mixture was shaken at 100 RPM at room 
temperature for 30 minutes. After the conjugation, the resin was washed three times with the 
buffer to remove excess protein, and then it was incubated with the foldamer sublibrary, where 
each library member was in a concentration of 1 or 10 μM in two different experimental setups. 
The library with the immobilized CaM was also shaken at 100 RPM at room temperature for 
30 minutes. The unbound fragments in the supernatant were removed from the resin for further 
analysis (unbound fraction, UF) and then 200 µl of 200 mM imidazole was added to the sample 
to elute the polyhistidine-tagged CaM and bound library members from the resin at room 
temperature for 5 minutes. Then, it was centrifuged as described previously. Negative control 
experiments were carried out using the same procedure in the absence of polyhistidine-tagged 
CaM to measure the nonspecific binding between the resin and the foldamer library. Collected 
samples were measured using HPLC-MS and Thermo Xcalibur 2.2 software was used for peak 
identification and integration. On the basis of HPLC-MS peak integration, relative fragment 
content (RFC) in the protein complex was calculated for each library member using the 
following formula: 
𝑅𝐹𝐶 (%) =
𝑐𝑖,𝑐𝑜𝑚𝑝𝑙𝑒𝑥 
∑ 𝑐𝑖,𝑐𝑜𝑚𝑝𝑙𝑒𝑥
𝑛
𝑖=1
 × 100 
where n is the total number of library members, ci,complex is the concentration of the fragment 
i in complex with the protein. The latter value was calculated for each library member by using 
the following equation:  
𝑐𝑖,𝑐𝑜𝑚𝑝𝑙𝑒𝑥 = 𝑐0 × (1 − 𝑢𝑛𝑏𝑜𝑢𝑛𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 (𝑈𝐹𝑖)), 
where c0 was equal with the initial concentration (1 or 10 µM) of the given fragment i. UFi 
was calculated from the ratio of i in the supernatant and in the control sample: 
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𝑈𝐹𝑖 =
𝐴𝑈𝐶𝑖,𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
𝐴𝑈𝐶𝑖,𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 
where AUCi, supernatant: area under the curve of the given fragment (i) in the supernatant, AUCi, 
control: area under the curve in the control sample. 
3.6. Generation of dynamic combinatorial library 
DCLs were prepared from Cys-functionalized building blocks each at a concentration of 10 
µM in a redox buffer [pH=7.4, 20 mM HEPES, 150 mM NaCl, 1 mM CaCl2, 3 mM NaN3, 500 
µM reduced glutathione (GSH), 125 µM oxidized glutathione (GSSG)]. CaM was used as a 
template in three different concentrations: 1 µM, 6 µM, 30 µM and a control DCL was started 
in the absence of template protein in parallel. Library was shaken at 37 °C, 250 RPM for 5 days 
in Eppendorf LoBind microcentrifuge tubes. At the beginning and every 24 h, 100 µl of reaction 
mixtures were taken for analysis and quenched with an equivalent volume of 10% TFA in water. 
All quenched reaction mixtures were analyzed using HPLC-MS, and library members were 
identified according to their mass and hydrophobic characteristics. Amplification factors (AFs) 
were determined as the component concentration ratio relative to the control experiment: AFi= 
AUCi, CaM / AUCi, control, where AUCi, CaM: AUC of compound i in the presence of CaM, AUCi, 
control: AUC of compound i in the control sample (without CaM). 
3.7. LC-MS methods and peak detection parameters 
HPLC/ESI-MS analysis was used to characterize the samples from the pulldown assay and 
the composition of DCLs. LC-MS analysis was performed with a Thermo Scientific Dionex 
UltiMate 3000 HPLC system interfaced to an LTQ ion trap mass spectrometer (Thermo 
Electron Corp., San Jose, CA, USA). Samples were injected onto a Phenomenex Aeris 
Widepore XB-C18 (250 × 4.6 mm, particle size: 3.6 µm, pore size: 200 Å) analytical HPLC 
column using gradient elution 5–80% solution B during 25 minutes with a flow rate of 0.7 mL 
min-1. For pulldown samples, eluent compositions were 0.1% acetic acid in distilled water 
(solution A) and 0.1% acetic acid in acetonitrile (solution B). DCL samples were measured at 
50 °C column temperature with 0.1% formic acid in distilled water used for solution A and 
0.1% formic acid in acetonitrile for solution B. Mass spectra were acquired in full scan mode 
in the 200 to 2000 m/z range. For overlapping peaks, selective reaction monitoring (SRM) was 
used. 
Thermo Xcalibur 2.2 software package was used for peak identification and integration. 83% 
of the foldameric fragments could be resolved separately via HPLC-MS/MS measurements 
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based on molecular weight, MS fragmentation pattern, and retention time considering the 
relative hydrophobicity of the side chains. Most of the unresolved peaks were foldamers that 
contained β3hIle or β3hLeu in position 5. These were integrated and averaged. Using ICIS peak 
detection algorithm[133], the general detection and integration criteria were the following: 
smoothing points 5, baseline window 80, area noise factor 5, peak noise factor 10. Using these 
processing setups, all raw data files were reprocessed together and analyzed. Errors in peak 
identification during the automatic processing were corrected manually. 
3.8. NMR experiments 
Structural analysis of the foldamers. Peptides were dissolved in 20 mM pH 7.0 d18-HEPES 
(90% H2O, 10% D2O) containing 0.02% NaN3 and 30 mM CaCl2 at concentrations of 90–500 
μM, depending on the solubility of the compound. NMR experiments were performed at 298 
K. 2D TOCSY measurements were carried out with homonuclear Hartman–Hahn transfer with 
a mixing time of 80 ms (DIPSI2 sequence). 2D ROESY spectra were recorded with a mixing 
time of 400 ms. The number of scans varied between 8 and 64, depending on the concentration 
of the sample. In order to assess the bound conformation of the ligands, 0.02 equivalent CaM 
was added to the samples and 2D NOESY spectra were recorded with a mixing time of 150 ms. 
Control NOESY spectra were recorded in the absence of the protein. 
15N HSQC titration experiments. Titration experiments were carried out on a Bruker Avance 
III 600 MHz spectrometer equipped with a 5 mm CP-TCI triple-resonance cryoprobe. 15N/13C 
CaM (Creative Biolabs, Shirley, NY, USA) was dissolved in 20 mM pH 7.0 d18-HEPES buffer 
(90% H2O, 10% D2O) containing 30 mM CaCl2 and 0.02% NaN3. Reference 2D heteronuclear 
15N-HSQC spectrum was acquired for the ligand-free CaM at a concentration of 45 μM at 30 
°C with 256 increments and 16 scans. Foldamers were added to the 15N/13C CaM sample in 
solid form (aliquoted and lyophilized from solutions) and 15N-HSQC spectra were measured 
again in the presence of the foldamers, resulting in a series of CaM spectra with 0.5, 1.0, 1.5, 
2.0, 3.0 and 4.0 equivalent peptides. Chemical shift assignment was based upon literature data 
and verified by standard triple-resonance NMR experiments. Processing was carried out by 
using Topspin 3.5 (Bruker) and processed data were analyzed with Sparky 3.114 (T. D. 
Goddard and D. G. Kneller, SPARKY 3, University of California, San Francisco). The chemical 
shift perturbation (CSP) values were calculated by using the formula [(Δδ(1H))2 + 
0.14*(Δδ(15N))2]1/2. 
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4. Results and Discussion 
4.1. Recognition of β-amyloid oligomers with multivalent foldameric 
conjugate 
From the aspect of molecular recognition, two major strategies can be followed to 
discriminate soluble aggregated Aβ from monomers in a sandwich-based biochemical test: i) 
application of a conformation-specific antibody as a capture antibody, ii) using the same 
sequence specific antibodies as the capture and the detection antibody at the same time. In the 
latter case, the concept is that two antibodies are only able to bind to the same antigen if there 
are multiple epitopes displayed. For Aβ, this is possible through aggregation. The antibody-
based Aβ capture schemes may cause false positives, because of the cross-reactivity of the 
capture molecules[134]; therefore, alternatives are sought to replace them. Taking advantages of 
fragment-based approach and surface mimetic properties of small ordered foldameric 
fragments, multivalent ligand was designed against Aβ42 oligomers[98]. Solvent exposed 
K16LVFFAE22 sequence of the amyloid was the starting point for bottom-up design of the 
recognition unit. We hypothesized that a basically hydrophobic molecule, which can form salt-
bridges with the complemetary part of the amyloid sequence, may selectively recognize the 
growing end of the oligomer. Testing a small set of pure β- and α/β- peptides, a hexameric 14-
helix proved to be the best for amyloid recognition containing β3hArg and β3hAsp at position 2 
and 5 of a scaffold based on (1S,2S)-2-aminocyclohexanecarboxylic acid (ACHC) (Figure 5, 
H1). The 14-helix is frequently applied template for proteinogenic side chain presentation, 
because three faces can be separated on its surface. In the case of H1, one face is for epitope 
presentation and two faces to form hydrophobic shield to protect ion-pairing interactions from 
water. Binding affinity of H1 towards Aβ was tested with different biochemical assays and it 
was successfully enhanced by coupling multiple copies of foldamers to a tetravalent zero 
generation poly(amidoamine) (G0-PAMAM). 
 
Figure 5. Structure of the foldameric recognition element: a) faces of the 14-helix projecting the 
proteinogenic side chains towards a surface, b) schematic representation and structural formula of H1. 
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4.1.1.  Design of the affinity assay for Aβ detection 
The multivalent foldameric conjugate mentioned above displayed low nanomolar binding 
affinity toward Aβ oligomer, which is comparable to the antibody–antigen interactions. In order 
to take advantage of this artificial antibody mimetic, our goal was to develop an easy-to-perform 
sandwich assay for selective detection of soluble Aβ oligomers. The general experimental setup 
of a sandwich ELISA assay (Figure 6) consists of a highly specific capture element, an antigen, 
a detection antibody for the recognition of antigen. and a secondary antibody suitable for 
colorimetric detection. 
 
Figure 6. Schematic representation of the sandwich ELISA setup. 
Our work focused on the optimization of the capture molecule and the immobilization 
strategy, which is based on the multivalent foldamer conjugate recognition element. For 
detection antibody, we utilized the anti-Aβ monoclonal mouse antibody 6E10, a commonly 
applied tool in Western blot techniques, immunhistochemistry, and ELISA. It recognizes the 
N-terminal end (residues 1–16) of Aβ, which segment is disordered and accessable even in the 
aggregated form. Accordingly, the secondary antibody was a horseradish peroxidase (HRP)-
conjugated anti-mouse antibody, where HRP was responsible for colorimetric detection. As a 
substrate of the enzyme, 3,3',5,5'-tetramethylbenzidine (TMB) solution was choosen, that 
undergoes oxidation by HRP enzyme yielding 3,3',5,5'-tetramethylbenzidine diimine with color 
change from yellow to blue. 
4.1.2. Structural optimization of the capture element 
As a first step of the optimization, the fine-tuning of the structure of the foldameric conjugate 
was carried out in two aspects. We investigated i) the effects of multivalency and geometry of 
the template and ii) the effects of the amino acid replacements in the sequence of the foldameric 
recognition fragment on Aβ binding. 
4.1.2.1. Effects of multivalency and the geometry of the template 
Sensitivity is a crucial parameter in the detection of Aβ aggregates. Because their 
concentration in body fluids is in the picomolar range in the early stage of AD[135], high-affinity 
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interaction is required for amyloid recognition. To further increase the amyloid binding 
efficiency and examine the effects of multivalency on Aβ binding, multiple H1 foldamers were 
coupled to different scaffolds. In this work, the identifiers of the compounds consist of four 
digits: 1. symmetry (C: central, F: focal) – 2. valency of the conjugate (2–8) –3. and 4 – H and 
the number of the recognition unit (1–9). Any kind of tags directly attached to the scaffolds are 
indicated at the beginning of the compound names, and tags at the N-terminal of the foldamer 
are indicated at the end of the identifier. Besides the di- and tetravalent-conjugates studied 
previously (Table 2, C2-H1 and C4-H1), tri- and octavalent conjugates were designed having 
central symmetry (C3-H1 and C8-H1). It was reported earlier that a foldameric fragment alone 
(H1) and a divalent ligand (C2-H1) can show low micromolar and submicromolar (high 
nanomolar) interaction with Aβ sample, respectively. For trivalent compound C3-H1, low 
nanomolar KD was obtained close to the dissocation constant of the tetravalent conjugate C4-
H1. In addititon, it showed two-stage interaction with Aβ oligomers in isotermal titration 
calorimetric (ITC) measurements. Good correlation was found between the binding affinities 
and the valencies of the conjugates. Interestingly, however, the increase of the number of arms 
from four to eight did not improve the affinity further (Table 2). From the stoichiometry data, 
it was transparent that C4-H1 makes a 1:4 high-affinity complex with Aβ (referenced to the 
concentration of the monomers) at the first binding stage, and the high-affinity interaction does 
not require more than four foldameric capture segments. 
Table 2. Effects of multivalency on Aβ binding. 
Conjugate Scaffold Valence KD (nM-1)* 
H1 - 1 2376.1 ± 214.4 
C2-H1 1,4- di(maleimido)butane 2 721.4 ± 120.1 
C3-H1 tris(2-(5-aminopentanamido) ethyl)amine 3 
18.5 ± 13.91 
155.0 ± 130.92 
C4-H1 generation zero poly(amidoamine) dendrimer 4 
6.9 ± 1.41 
281.1 ± 38.72 
C8-H1 generation one poly(amidoamine) dendrimer 8 
69.0 ± 12.01 
193.4 ± 30.52 
*based on ITC experiments 
1 and 2 belong to the first and the second binding stages 
„C” in the name of the compound refers to the central symmetry and the number indicates the valency 
In sandwich ELISA experiment, the antibody is usually immobilized on the surface of a 96- 
or 384-well plate by passive adsorption. The Fc region of the protein is generally more 
hydrophobic and, therefore, more likely to be absorbed, than the Fab region, which remains 
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mostly accessable to the antigen. In the case of a synthetic molecule, oriented immobilization 
is particularly essential to ensure effective analyte binding. Avidin–biotin is known as one of 
the strongest and most specific non-covalent interaction in nature, with dissociation constant in 
the femtomolar range (KD= 1.3 x10
-15 M at pH 5.0)[136]. It has been exploited in the detection 
of many biomolecules, purification techniques, and labelling strategies. Using this interaction 
in the immobilization is especially preferred in our case due to the small size of biotin, which 
can be easily coupled to the peptide even by solid-phase peptide synthesis. During optimization, 
two biotinylation strategies were followed. First, biotin-tag was directly coupled to the N-
terminus of the foldamer sequence, which gave H1-B, and then it was conjugated to G0-
PAMAM dendrimer having central symmetry (Figure 7, C4-H1-B). Second, biotin-tag was 
placed in the focal point of an oligo-L-lysine dendron by coupling N-ε-biotinyl-L-lysine (B-F4-
H1). Figure 7 represents the major structural differences between these two scaffolds. 
 
Figure 7. Schematic representation of the branched templates: a) centrally symmetric dendrimer and 
C4-H1-B conjugate immobilized on a surface, b) dendron having a focal symmetry and arrangement 
of the foldamer helices in immobilized B-F4-H1, where F refers to focal symmetry. 
Binding efficiencies of the capture elements were quantified in ELISA experiments and 
significant differences were found. EC50 value for C4-H1-B was 648.5 ± 11.2 nM and for B-
F4-H1 the EC50 was three orders of magnitude lower (0.97 ± 0.04 nM) indicating higher affinity 
towards Aβ sample (Figure 8). Both dendrimers and dendrones are fully branched in the 
solution phase. However, it is likely that biotinylation at the root of a lysine-dendron yields an 
immobilized conjugate, in which the helical units may freely point away from the surface. In 
contrast, C4-H1-B uses one of its foldamer fragments to anchor the conjugate to the surface, 
which prevents presenting all foldamer helices toward the solution phase necessary for high-
affinity binding. Another possible reason for the decrease in efficiency can be that biotinylation 
capped the free N-terminal amino group of the foldamer, which may have critical role in 
recognition. In order to confim this hypothesis, an N-terminal acetylated form of the recognition 
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fragment (Figure 9, H1-Ac) was synthesized and linked to tetravalent lysine dendron (B-F4-
H1-Ac). In ELISA experiment, we measured increased EC50 value (30.16±2.27 nM) for the 
acetylated conjugate compared with the non-acetylated one, which highlighted the importance 
of the free N-terminals in high-affinity binding. Since it was still better than C4-H1-B we could 
conclude that the accessibility of all four foldamer arms is also an essential requirement. 
 
Figure 8. Results of the ELISA experiments. Comparison of the affinities of the immunoassay for C4-
H1-B (red), B-F4-H1-Ac (green), and B-F4-H1 (blue) as capture elements. Absorbances were 
normalized to the maximum value in each experiment. 
4.1.2.2. Effects of side shain alterations in the foldamer segment on Aβ binding 
Although the number of arms of the multivalent conjugate and the topology of the scaffold 
is crucial for high-affinity binding, only the foldameric fragments are responsible for selective 
recognition of the Aβ oligomers. To study the role of certain structural elements of the foldamer 
in the binding, a set of new foldamer sequences was designed and attached directly to a biotinyl-
tetravalent oligo-L-lysine dendron (B-F4) to make them applicable in ELISA as capture 
molecules. 
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Figure 9. Compounds designed for Aβ recognition. Identifier, sequence, and schematic representation 
of the recognition units. 
Structural changes included fine-tuning the properties of the proteinogenic side chains 
(H2/3/4), changing the relative position of ionic residues (H5), and introducing bulky bicyclic 
side chains in different positions (H6/7/8/9). Binding affinites of biotinyl–tetravalent 
conjugates (B-F4-H1/2/3/4/5/6/7/8/9) were tested in ITC and ELISA experiments. In the cases 
where the ITC curve fitting failed due to low heat response or poor solubility, only the ELISA 
results provided information about the binding. As B-F4-H1 contains the initial binding 
sequence, the effectivities of the further conjugates were compared to it. All evaluated ITC 
results showed two-stage binding behavior as in the case of F4-H1. In comparison with the 
biotinylated version, the binding affinites are similar low nanomolar in ITC, which supports 
that biotin has a negligible effect in the solution-phase binding assay. 
Table 3. Thermodynamic parameters resulting from ITC analysis for conjugates and estimated EC50 
values from quantitative evaluation of ELISA experiments. 
Compound KD (nM-1) ΔG (kcal M-1) ΔH (kcal M-1) -TΔS (kcal M-1) EC50 (nM) 
B-F4-H1 27.63 ± 7.741 
239.62 ± 68.672 
- 9.97 
- 8.73 
51.33 
0.31 
61.30 
9.04 
0.95 ± 0.06 
B-F4-H2 53.20 ± 38.701 
373.40 ± 104.332 
- 9.59 
- 8.78 
6.57 
0.64 
16.16 
9.42 
5.36 ± 1.42 
B-F4-H3 2.53 ± 1.811 
175.20 ± 46.412 
-11.34 
- 8.91 
1.96 
0.76 
13.30 
9.67 
1.92 ± 0.21 
B-F4-H4 nd nd nd nd 7.70 ± 3.06 
B-F4-H5 nd nd nd nd 2.71 ± 0.21 
B-F4-H6 19.30 ± 9.401 
816.40 ± 466.902 
- 10.17 
-8.03 
2.48 
0.27 
12.66 
8.30 
1.79 ± 0.09 
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B-F4-H7 34.10 ± 10.001 
652.30 ± 158.502 
- 9.85 
- 8.16 
4.88 
0.37 
14.73 
8.53 
1.34 ± 0 04 
B-F4-H8 8.61 ± 5.641 
78.99 ± 45.922 
-10.64 
-9.37 
7.39 
0.35 
18.02 
9.72 
1.35 ± 0.08 
B-F4-H9 nd nd nd nd 1.59 ± 0 08 
nd= not determined. 1KD belongs to the first binfing stage. 2KD belongs to the second binding stage. 
It has been shown previously, that removal of the ionic residues of the foldamer fragment 
(replacement of both β3hArg and β3hAsp to β3hSer) resulted in a KD value with one order of 
magnitude higher[98]. Homologous replacements of the charged side chains modulated the 
affinity, but they could be basically tolerated. The β3hArg to β3hLys exchange (B-F4-H2) 
caused a decreased affinity at the first binding stage, whereas the change of β3hAsp to β3hGlu 
(B-F4-H3) led to somewhat improved properties in ITC. The effects of the β3hArg to β3hLys 
replacement can be explained by the structural differences between the charged side chains. In 
contrast to Lys, where the charge is localized on the terminal aliphatic amino group, the positive 
charge of Arg is delocalized within the π-bonded system of the guanidinium ion, resulting in a 
considerably different charge distribution and geometry. This makes arginine capable of 
multiple types of favorable interactions; thus, Arg is preferred as hot-spot residue compared to 
Lys[137]. For B-F4-H3, the results suggested that the presence of the negatively charged residue 
in position 5 is essential for the binding[98], but the length of the side chain did not have an 
important role. In the ITC experiment of B-F4-H4, in which we changed β3hAsp to Asp, and 
β3hArg to Arg, the observed low ΔH made the analysis difficult. A similar low-heat response 
was found for B-F4-H5, where we changed the position of the positively charged residue 
(β3hArg) in the helix, resulting in failed fitting. A systematic ACHC to (1S,2S,3S,5R)-3-amino-
6,6-dimethylbicyclo[3.1.1]heptane-2-carboxylic acid (ABHC) replacement was also carried out 
along the chain (B-F4-H6/7/8/9), and we found that this approach did not lead to a significant 
increase in the affinity in the first binding stage (Table 3). C-terminal ACHC to ABHC 
replacement in the helix (B-F4-H9) considerably decreased the solubility of the conjugate, 
which made the dissolution difficult and, therefore, KD could not be determined under these 
conditions. 
The EC50 values for the complete set of new conjugates were calculated individually from 
the data of the ELISA experiments as well. Comparing the EC50 values of B-F4-H6/7/8/9, the 
replacement of ACHC to ABHC had only a minor effect on the Aβ binding. The cyclic β-amino 
acid ACHC not only stabilizes the helical conformation of such a short foldamer, but also 
shields the electrostatic interactions from the solvent upon binding, due to its bulky nature. 
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Increasing the bulkiness of the helix by a substitution of ACHC with a bicyclic amino acid in 
the recognition element resulted in a retained binding affinity to Aβ. On the other hand, 
changing only one ACHC to ABHC in the foldamer sequence significantly decreased the 
solubility of the conjugate. In the ELISA experiment, the EC50 values for B-F4-H4 and B-F4-
H5 could be determined observing increased values compared with B-F4-H1. For B-F4-H4, 
the results indicated that the simultaneous replacement of β3hArg and β3hAsp to the α-
analogues could be moderately tolerated. The β3 to α exchange gave βαββαβ backbone pattern 
that could alter the folding behaviour of the hexamer[87]. This finding revealed the importance 
of the conformation of the helical recognition segment. Interestingly, changing the relative 
position of the charged residues (B-F4-H5) within the helix did not influence the binding of the 
molecule to Aβ considerably. Consequently, some flexibility may be assumed regarding the 
structure of the foldamer. Since we did not find more effective recognition unit, B-F4-H1 was 
used as a capture element for further optimization of the enzyme-linked immunoassay. 
4.1.3.  Detection of Aβ oligomers in ELISA 
Since the concentration of the Aβ oligomers in the early stage of AD is in a low picomolar 
range, a highly sensitive method was needed for quantitative measurements. The quantification 
of the foldamer–amyloid complex was achieved by measuring the absorbance of TMB diimine 
at 370 nm. With a large excess of substrate present, the recorded intensity depended on the 
concentration of the enzyme, but the ratio of HRP to antibody was constant for a given batch 
of antibody. Therefore, the amount of the enzymes taking part in the colorimetric reaction could 
not be further increased by enhancing the concentration of the secondary antibody. An HRP-
polymer tagged secondary antibody (Histols-M) increased the sensitivity of the system due to 
the higher number of HRPs bound to the polymer. As a result, we found intense immunostaining 
without background (Figure 10a). Another important parameter influencing sensitivity is the 
steric hindrance between the immobilized capture molecules, which may limit the performance 
of the detection. The effects of steric crowding were tested by the variation of the surface 
coverage. Experiments were carried out with plates precoated by streptavidin with surface loads 
of 60 pmol and 125 pmol per well. Although the EC50 value did not change with the surface 
load, higher intensity was recorded for the 60 pmol plate (Figure 10b) indicating that it is the 
HRP-polymer tagged secondary antibody, which performs better if steric hindrance is 
decreased. 
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Figure 10. Optimization of the ELISA setup. a) recorded absorbance values at 370 nm as a function of 
Aβ concentration: green circle: initial conditions (surface loading: 125 pmol well-1; HRP-conjugated 
secondary antibody), red triangle: surface loading: 125 pmol well-1, Histols-M secondary antibody; 
black square: surface loading: 60 pmol well-1 plate, Histols-M secondary antibody. b) Result of the 
ELISA experiment using the optimized conditions; the inset shows the linear dependence of intensity 
on Aβ concentration between 10–500 pM. 
Utilizing the improved capture ligand B-F4-H1 and the optimized protocol, the limit of 
detection (LOD, defined as three times the standard deviation of the blank) was estimated to 5 
pM (n= 12), and linear dependence of intensity on Aβ concentration was found over the 
concentration range 10–500 pM (Figure 10b, R2 = 0.9974). 
The selectivity of the assay toward the Aβ oligomers was tested using both predominantly 
monomeric and oligomeric Aβ samples. The Aβ solutions with different aggregation states were 
prepared according to literature protocols[98]. The monomeric and oligomeric samples were 
checked in parallel with a commercially available Aβ monomer-selective ELISA kit 
(Innotest®) commonly utilized in clinical studies. For ELISA performed with the capture 
element B-F4-H1, concentration-dependent signal was observed for the oligomeric sample in 
the range 0–200 pM (Figure 11a). The fresh monomeric Aβ did not yield signal in this 
concentration range (LOD estimated to be 3600 pM). In contrast, the monomer-sensitive 
commercial sandwich ELISA kit produced concentration-dependent signal for the monomeric 
Aβ sample (Figure 11b). At the same time, a relatively low-intensity response was detected 
above 100 pM for the aggregated Aβ sample, which can be attributed to the residual monomeric 
Aβ content. These results revealed that capture ligand B-F4-H1 is selective for the Aβ 
oligomers, and the foldamer-based sandwich ELISA assay gives complementary response to 
the monomer Aβ selective kit. 
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Figure 11. Confirmation of the oligomer selectivity of the assay. Measured signals of the predominantly 
monomeric samples (red circle) and oligomeric samples (blue triangle) in a) the foldamer-based 
sandwich assay (capture molecule: B-F4-H1, detection antibody: 6E10, secondary antibody: Histols-M, 
recorded signal: absorbance of TMB diimine at 370 nm), b) the commercially avaliable ELISA test 
(Innotest®) designed for the quantitative determination of Aβ42 in human CSF (capture antibody: 
21F12 monoclonal antibody, detection antibody: biotinylated 3D6 antibody and HRP-labeled 
streptavidin, recorded signal: absorbance of TMB diimine stabilized with 0.45 M H2SO4 at 450 nm). 
It was also reported earlier that foldamer conjugate C4-H1 cannot bind fibrillar Aβ with high 
affinity in the solution phase, suggesting that our ELISA method is capable of monitoring the 
aggregation state of an Aβ solution by detecting solely the oligomer content. A standard Aβ 
aggregation procedure (incubation of a freshly disaggregated Aβ monomer sample at the 
concentration of 50 µM, 37 °C for 24 hours) was carried out and samples were taken at regular 
intervals. Samples were diluted to a total Aβ concentration of 500 pM, then applied onto the 
ELISA plate. The recorded absorbances increased with time, then the intensity reached a 
plateau after 3 hours (Figure 12), which remained constant until 18 hours, when the absorbance 
started to decline. 
  
Figure 12. Monitoring time-dependent aggregation of Aβ. Absorbane values were recorded for 500-pM 
samples diluted in situ at each time point. 
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Towards the end of the experimental run (18 h), aggregation transformed the oligomers and 
residual monomers to fibrils, which did not show affinity to B-F4-H1. These results strongly 
suggested that this system is able to indicate the state of an ongoing aggregation in a pM sample. 
This finding, together with the observation that the binding affinity of the tetravalent ligand 
cannot be improved further by increasing the valence, we could speculate that foldameric 
conjugate recognizes transient Aβ surface features of oligomers rather than general repeating 
features of the cross-β-sheet surface of the aggregates. We note that the quantification of 
fibrillar Aβ is not possible, because of the disaggregation of the pure fibrillar form into 
oligomeric and monomeric forms[138] at low picomolar concentration. Therefore, selectivity of 
our foldamer-ELISA assay against the fibrillar form cannot be clearly concluded from these 
data. 
4.2. Bottom-up design approach for recognition of separate hot spots 
Calmodulin (CaM) is a commonly used model for protein recognition and inhibition 
studies[26, 139]. It was selected as a model protein, which has two separate hot spots formed by 
the symmetrical globular domains, due to its flexibility and structural diversity of its binding 
partners. Our hypothesis was that the target hot-spot pockets could be mapped using short 
foldameric segments mimicking the local environment of hot-spot residues in terms of side-
chain presentation and solvent shielding (Figure 13a). In order to address the problem of 
simultaneous optimization of both the recognition segments and the linkage, a dynamic 
covalent library (DCL) method was developed (Figure 13b).  
 
Figure 13. The concept of the foldameric ligand design strategy: a) mapping the hot spot pockets of the 
protein with the helical foldamer library and b) optimization of the foldameric ligand using dynamic 
combinatorial chemistry. 
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4.2.1. Design of the foldamer library 
A 14-helix was used as a template for the presentation of proteinogenic side chains due to 
its favorable properties mentioned above. The structure of the helix was stabilized by (1S,2S)-
2-aminocyclohexanecarboxylic acid (ACHC) and β3-homologs of 16 different α-amino acids 
were placed both to positions 2 and 5 of the hexamer. The variable open-chain residues in 
juxtaposition pointed into the same direction presenting side chains for molecular recognition. 
The highly hydrophobic cyclohexane side chains ensure the exclusion of solvent from the 
shallow binding cleft. 
To simplify the production and the HPLC-MS analysis of the 256-membered library, it was 
divided into four sublibraries each containing 64 members (Figure 14). On the basis of the 
characteristics of β3-amino acid at the 2nd position, the sublibraries have aromatic (L1), charged 
(L2), aliphatic (L3), and polar (L4) side chains.  
 
Figure 14. Structural formula and schematic representation of folded segments and the composition of 
the sublibraries. 
The synthesis of the sublibraries was carried out by microwave assisted solid-phase peptide 
synthesis. To ensure complete representation of each foldamer fragment, double coupling of 
sub-stoichiometric amount of Fmoc-protected β3-amino acid mixtures was applied. After 
purification, each foldameric fragment was identified via HPLC-ESI-MS/MS methods. Taking 
into account multiple charge states for every single peptide, the purities of the libraries were 
found between 69–84% (Figure 15) with acceptable equimolarity[140, 141]. 
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Figure 15. Estimated equimolarity and purity of the 64-membered sub-libraries: a) L1, b) L2, c) L3, d) 
L4. Names of the compounds are generated from the single-letter amino acid codes of the β3-amino acid 
used in the position 2 and 5 of the sequence. Equimolarity was calculated using the following formula: 
AUCcompound/(AUCtotal/number of library members); thus, relative value of 1 indicates equimolar 
concentration. Purity was estimated using the following formula: AUCcompound/AUCtotal × 100. 
4.2.2. Screening of the library members 
Generation of a ditopic DCL from 256 peptidic compounds would result in a very complex 
mixture (theoretically 33280 different compounds). Keeping the concentration of the 
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fundamentally hydrophobic dimers above the detection limit and their quantification are not 
possible; thus, careful selection of the members of the DCL is necessary. Therefore, we first 
ranked the fragments based on their affinity towards CaM in a pulldown assay. Foldamer 
sublibraries were incubated with the immobilized protein and all unbound fragments were 
quantified in the supernatant. After the elution of the protein–foldamer complexes, the bound 
components were analyzed in the eluted fraction as well. In two separate measurements, 
fragments were applied in two different concentrations. First, the whole library was quasi-
equimolar with the protein (library:protein = 1:1), i.e., all fragments have the opportunity to 
bind to the template without competition. Second, the library was applied in a ten-fold molar 
access to the protein (library:protein = 10:1) eliciting significant competition between the 
library members. Foldamers indicated in blue displayed very low tendency to form complexes 
with CaM (Figure 16). Concerning the acidic characteristic of the protein (pI 4.09), it is not 
surprising that Glu and Asp side chains are not preferred as hot-spot residues. However, almost 
all other fragments containing at least one aromatic or aliphatic side chain made complexes 
with CaM (Figure 16a). Due to the competition between the library members in the 10:1 
composition, the enrichment of some fragments increased at the expense of those with lower 
affinity (Figure 16b). Aromatic side chains are still preferred by the protein especially 
tryptophan and basic residues containing β3Arg or β3Lys in position 2 made stable complexes 
with CaM. Our results were in line with the known binding partners of CaM[139], as they 
generally contain Trp residues that fit the Met-rich hot spots of CaM. The enrichment pattern 
of the fragments depended on the specific composition of the sublibrary. On the basis of results 
of the pulldown experiments, promising hits were identified to create a focused library for the 
DCL experiments. 
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Figure 16. Results of the pulldown assays. Enrichments of the fragments in the protein complexes in 
two different experimental setups: library-to-protein compositions in a) 1:1 and b) 10:1. The relative 
fragment content was calculated for each library member using the indicated formula as described in the 
experimental section. 
4.2.3. Characterization of protein binding with selected foldameric 
fragments 
On the basis of the results of the pulldown assays, the best candidate from each sublibrary 
was selected to validate and quantitatively characterize the interactions with CaM. The selected 
foldamers (WF, RW, LW, TW) were re-synthesized individually and the nomenclature is 
according to the standard one-letter codes of the proteinogenic side chains presented by the β3-
residues in positions 2 and 5. In order to investigate the importance of the bulky, ordered 
secondary structure, a non-helical derivative of WF was synthesized (rrWF), where the 
replacement of the 1S,2S-ACHC in position 4 to its enantiomer pair (1R,2R-ACHC) prevented 
helix formation according to the stereochemical patterning approach[17]. ITC experiments were 
performed to identify the thermodynamic parameters of the binding. Low micromolar-
submicromolar KD values were found (Table 4). The titration curves were fitted against the two 
independent binding sites model and indicated that CaM binds uniformly two foldamer 
segments at the same time (Table 4, Figure 17). The non-helical rrWF did not show any 
interaction with the target protein, which highlights the importance of the folding on binding. 
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The negative ΔH values are accompanied by negative entropy changes for most fragments 
(Table 4) suggesting multiple favorable noncovalent interactions between the foldameric 
fragments and the protein. For LW, a large negative entropy gain was found accompanied by a 
positive enthalpy change, suggesting that the interaction is mostly driven by solvophobic 
effects. The large negative ΔH for WF showed that the interaction is enthalpy driven and 
indicated that the binding is not dominated by the hydrophobic effects, which is an 
advantageous characteristic for drug design[142]. 
Table 4. Thermodynamic parameters of fragments binding to CaM. 
Compound KD ITC (µM) n ΔH -TΔS KD Trp (µM)* 
WF 0.076 ± 0.004 2.11 ± 0.01 -6.79 ± 0.04 -2.41± 0.05 0.065 
RW 0.706 ± 0.007 1.97 ± 0.02 -2.72 ± 0.00 -5.40 ± 0.01 1.780 
LW 0.139 ± 0.014 1.98 ± 0.03 0.78 ± 0.02 -9.83 ± 0.04 0.514 
TW 17.107 ± 1.102 1.82 ± 0.09 -4.3 ± 0.10 -2.0 ± 0.10 n.d. 
rrWF n.d. n.d. n.d. n.d. n.d. 
*estimated KD from Trp titration experiments 
Excitation of Trp-containing peptides results in fluorescence emission in the range 300–400 
nm depending on the local enviroment of the indol ring. Upon transfer from solvent-exposed 
polar enviroment to a hydophobic binding pocket, the emission maximum shifts from 350 nm 
to 330 nm[143, 144]. Since all selected foldamers contained Trp side chain, we could measure the 
blueshift of their side chain fluorescence emission to study Ca2+ dependency of the interaction 
and to obtain independent estimation of the KD of the binding. By titrating the solution of a 
given fragment with CaM, blueshift was observed for WF, RW, LW, and TW but not for 
rrWF (Figure 17). The phenomenon was not detected in the absence of Ca2+, which confirmed 
that the Ca2+-bound active conformation of CaM is essential for the recognition. The estimated 
KD values were determined for WF, RW, and LW (Table 4), which showed the same trend as 
those observed by ITC. 
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Figure 17. ITC and Trp fluorescence titration data for the selected fragments. ITC titrations showing 
raw data (upper) and integrated enthalpograms with fitted curves. Bottom line: fitted titration curves for 
the Trp fluorescence titrations. 
The propensity to fold into H14-helix in aqueous buffer was confirmed by ROESY 
experiments on WF, RW, LW, and TW (Figure 18), and long-range i–i+3 inter-residue 
interactions were detected. Sequence rrWF did not show any sign of binding and exhibited 
disorder in water thus supporting the necessity of the compact and bulky structure for CaM 
binding. 
 
 Figure 18. ROESY spectra for foldameric fragments. NOE interactions showing the helicity of 
compounds. Overlaid TOCSY (red) and ROESY (blue) spectra for compounds in the absence of the 
protein. Color-coded chemical shift assignment and detected i–i+3 type long-range interactions 
characteristic for the 14-helix, are indicated on the structures. 
RW and TW, having micromolar affinities with their fast exchange afforded transferred 
NOESY (tr-NOESY) measurements, which confirmed the 14-helical conformations in the 
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bound state as well (Figure 19a, b). In order to locate the binding site of the foldamers, their 
interactions with CaM were tested with 15N-HSQC NMR spectroscopic titrations, which were 
conclusive for RW and LW due to sufficient affinity and signal-to-noise ratio (limited line 
broadening). Significant chemical shift perturbation (CSP) and/or resonance broadening were 
observed for target residues L39, M36, M71, M72, M109, M144, and M145 (Figure 19c, e), 
which are key residues in the CaM–protein contacts and creating the hot spot pockets in the N- 
and C-terminal EF-hand motifs[145]. 
 
Figure 19. Results of the NMR spectroscopic investigations of foldameric fragments. Tr-NOE 
interactions showing the helicity of the CaM-bound compounds a) RW and b) TW; overlaid TOCSY 
(red) and NOESY spectra acquired with a mixing time of 150 ms (blue). The cross-peaks in the 2D 
NOESY spectra suggest 14-helix structure of the bound peptides. c) CSP of CaM in the presence of LW 
equivalents of 2. Residues with extreme resonance broadening (complete disappearance) are marked 
with a cyan line. The CSP values were calculated using the formula [(Δδ(1H))2 + 0.14 × (Δδ(15N))2]1/2. 
Dashed lines indicate the mean+standard deviation of the CSP values for the individual titrations, which 
are used as threshold. d) Residues with CSPs above the threshold (red) and the highest resonance 
broadening (cyan) mapped to the ribbon representation of CaM (PDB code: 2K0E[146]), e) and f) CSPs 
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of CaM in the presence of RW equivalents of 3; residues with CSPs above the threshold (red) and the 
highest resonance broadening (cyan) mapped to the ribbon representation of CaM. 
4.2.4. Affinity enhancement with dynamic combinatorial chemistry 
Twelve different hits were subjected to a target-templated DCL experiment. Three members 
of each sublibrary were re-synthesized with Gly-Gly-Cys at the C-terminals to prepare DCL 
through thiol–disulfide exchange reaction[147]. The initial concentartion of each library member 
was 10 µM in glutathion redox buffer, and the product distributions were analyzed by HPLC-
MS in the presence of different protein template concentrations (1, 6, and 30 µM). The reaction 
mixture reached the thermodynamic equilibrium after 96 hours of incubation: the composition 
of the solution did not change any more and the same product distribution was obtained from 
different starting mixture compositions (Figure 20). 
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Figure 20. Assessing thermodynamic equilibrium. Total ion chromatograms for DCLs with different 
mixture compositions at 0 h and pre-equilibrated at 48 h: a) library containing all twelve bulding blocks 
at 10 µM, b) and c) libraries containing components in the two separate red boxes above. The pre-
equilibrated mixtures b) and c) were pooled after 48 h and the product composition was analyzed after 
72 h (d) and 96 h (e). The final product distribution was compared with the total DCL (blue). After 96 
h, only slight differences could be detected between the pooled sample (red) and the control sample 
(blue). This showed that thermodynamic equilibrium has been reached after 96 h independent of the 
starting conditions. 
Through quantitative evaluation of the HPLC-MS total ion chromatograms, 102 compounds 
were identified, and the amplification factor was defined for each component by compairing 
the amount of product in the presence of CaM with that in the control sample (Figure 21). A 
four-fold increase in the maximum amplification was found as we increased the template 
concentration from 1 to 30 µM. However, in line with the literature[148], better selectivity was 
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obtained by keeping the building block to template ratio at high level. From the amplification 
data thus acquired, it is clear that hydrophobic/aromatic side chains are necessary but not 
sufficient for high-affinity binding, because under all three conditions dimers with at least one 
basic side chain are amplified. Interestingly, the homodimers of the best binder fragments (e.g., 
WF-SS-WF) were not amplified despite the quasi-equivalent binding sites on the protein. This, 
however, may not be surprising since, in the presence of a large excess of template, 
heterodimers can easily suppress better binder homodimers[148]. Nevertheless, it was found even 
at 1 µM CaM pointing to an emergent feature originating from the system chemistry approach. 
 
Figure 21. General structural formula and the list of the DCL building blocks (a) and b) results of the 
DCL experiments at three different CaM concentrations. The amplification factor was defined as the 
ratio of the AUCs in the presence of template and in the control sample without the protein. Color scales 
from blue to red indicate the lowest to highest amplification factor, respectively. „GSH” refers to 
glutathione adducts and „free” labeled line shows the amplification of a given monomeric building 
block. 
4.2.5. Characterization of the interaction between CaM and the high-
affinity ligand 
Heterodimer LW-SS-RW composed of LW and RW fragments showed the highest 
amplification under the most selective experimental conditions; therefore, this was selected as 
the best ligand. To improve the synthetic efficiency and stability in water, the disulfide bond 
was replaced by a thioether linkage resulting in LW-S-RW (Figure 22a). A two-stage high-
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affinity interaction was found between CaM an LW-S-RW (Figure 22c) by ITC. The first 
binding step displayed a KD of 1.54±0.16 nM with n = 1.04, which is two orders of magnitude 
lower than that of the monomers. 
 
Figure 22. Structure of LW-S-RW and characterization of its interaction with CaM. b) Trp fluorescence 
titration experiment, c) ITC titration of CaM with LW-S-RW and d) with TRPV1784–798; e) and f) 
competitive ITC experiments to confirm the inhibitory potential of the foldameric ligand. 
The formation of the 1:1 complex confirmed that the separate hot spots on the protein were 
successfully targeted with the helix dimer. The second lower-affinity step with fractional 
stoichiometry was detected, which pointed towards the ability to crosslink protein molecules at 
micromolar concentration. Owing to the Trp content of the LW-S-RW, fluorescence titration 
experiments could be performed, which also showed Ca2+-dependent binding similar to the 
monomeric fragments. The estimated affinity was 30 nM, which probably represents the 
average of the mentioned two-step interaction in ITC (Figure 22b). The interaction between 
CaM and LW-S-RW was also investigated by NMR, in which significant decreases in intensity 
were found in the 1H-NMR methyl region (0.6–1.08 ppm) of the titrated 13C/15N-labeled CaM 
(Figure 23a). Significant signal broadening and peak disappearing were found in the 15N HSQC 
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spectrum (Figure 23b), that could be caused by the ligand, which crosslinked the proteins, 
thereby slowing down the tumbling rate. This finding together with the existence of the second 
binding stage in ITC confirmed the crosslinked, LW-S-RW-induced formation of CaM 
associates. 
 
Figure 23. NMR spectroscopic investigation of CaM–LW-S-RW interaction. a) 1H NMR methyl region 
of 13C/15N-labeled calmodulin without any ligand (black) and in the presence of 1, 2, and 4 equivalents 
of LW-S-RW (red, blue, and grey, respectively). The corresponding relative integrals between 0.6–
1.08 ppm are: 100%, 89%, 77% and 60% for the samples containing 0, 1, 2, and 4 equivalent LW-S-
RW, respectively; b) Selected region for the 15N HSQC spectrum of CaM alone (red) and CaM in the 
presence of 1 equivalent of LW-S-RW (blue). 
CaM is a multifunctional Ca2+-binding protein expressed in almost all eukaryotic cells. It 
has a large number of protein binding partners including interaction with transient receptor 
potential vanilloid 1 (TRPV1)[149]. This was selected as a model system to test the inhibitory 
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potential of LW-S-RW. In the ITC experiment, the 15-mer peptide fragment TRPV1784–798 
forms a 1:1 complex with a dissociation constant of 30.9±2.1 nM (Figure 22d). After saturation 
of the CaM with its native ligand, the complex was titrated with the foldamer and an increased 
apparent KD was found for the first binding step (Figure 22e). If the CaM was first saturated 
with LW-S-RW and titrated with TRPV1784–798, the apparent affinity increased to the 
micromolar range (Figure 22f). These competitive ITC experiments confirmed that the 
foldameric ligand can compete with a native ligand, and it can successfully block their 
interaction 
5. Conclusions 
Prior works have reported the effectiveness of foldamers in molecular recognition, but in 
contrast to top-down approaches, bottom-up strategies are not frequently used for development 
of foldameric PPI inhibitors. In the present study, de novo bottom-up developments of high-
affinity foldameric ligands were carried out against difficult protein targets. 
Selective recognition of an oligomeric β-amyloid was achieved by the presentation of 
multiple copies of β-peptides designed as complementary binding surfaces to amyloid 
KLVFFAE motif. As a result of structural optimization, a tetravalent conjugate was synthesized 
using oligo-L-lysine dendron as a scaffold, which ensured low nanomolar binding affinity 
towards Aβ. A foldamer-based ELISA assay was designed using the foldamer-dendron 
conjugate as a capture element. After detailed optimization, a highly-sensitive affinity assay 
was developed with 5 pM as the limit of detection, which is comparable to purely antibody-
based detection methods. Our test is capable of monitoring the aggregation state of amyloid 
since it is selective to Aβ surface patterns, transiently present during the ongoing aggregation 
process. To the best of our knowledge, this is the first application of foldameric sequences in a 
biochemical assay. 
Simultaneous targeting of two separate hot spots of protein was utilized through systematic 
testing of a foldameric fragment library. A diverse 256-membered foldamer fragment library 
was designed and synthesized, and its binding affinity to CaM as model protein was tested in 
pulldown assays. The number of enriched fragments and the side-chain chemistry were in line 
with the pleiotropic behavior of the protein and the common structural motifs of its binding 
partners. This confirmed the ability of foldamer library to mimic protein surface patches. 
Selected foldameric fragments could simultaneously recognize the separate hot spots by 
forming 2:1 complexes with CaM. Their low micromolar binding affinities displayed the 
maximum achievable affinity, through projecting only two interacting side chains towards the 
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surface. With 15N-HSQC titration, residues, known to be key residues in the CaM–protein 
contacts, were identified. For the first time, dynamic combinatorial chemistry was used for 
development of foldameric ligands that recognized discontinuous hot spots. Considering the 
guidelines of DCL formation, an amplification study was carried out, that resulted in a 
heterodimeric foldamer ligand with a significantly improved binding affinity towards CaM. The 
existence of the 1:1 complex in ITC revealed the simultaneous recognition of the hot spots by 
a single foldameric ligand. Moreover, the dimer proved to be an effective inhibitor of CaM–
vanilloid receptor interaction. 
This study presented two different bottom-up approaches for efficient optimization of 
foldameric ligands. First, following the steps of the fragment-based drug design, functional 
mimetic of the molecular recognition properties of an antibody was prepared. The specific 
arrangement of multiple copies of epitope mimetics made the foldameric conjugate applicable 
to be utilized in a sensitive biochemical assay. In the second part of this work, a feasible 
synthetic strategy was elaborated in detail leading to a high-affinity foldameric PPI inhibitor by 
combining HTS of local surface mimetics and their dynamic covalent coupling. 
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6. Summary 
1. Utilizing the interaction between a previously studied antibody mimetic tetravalent 
foldamer–dendrimer conjugate and β-amyloid, a sandwich type analytical biochemistry 
assay was designed for detection and quantification of aggregated β-amyloid species in low 
nanomolar concentration. 
1.1. 16 different conjugates were designed and produced by convergent synthesis to study 
the relationship between the structure of the foldameric ligand and binding affinity to 
β-amyloid. A rising trend in efficiency was observed by increasing the number of arms 
of the conjugate, but the low nanomolar affinity could not be further enhanced by 
introducing an octavalent template instead of a tetravalent. 
1.2. Linking the 14-helix foldamers to a tetravalent oligo-L-lysine dendron scaffold resulted 
in a branched conjugate that binds to β-amyloid with high affinity similar to foldamer-
dendrimer, but it had more favorable properties for immobilization. Foldameric 
fragments on an oligo-L-lysine dendron were successfully used as capture elements in 
a sandwich ELISA experiment. 
1.3. The optimized assay was able to distinguish between β-amyloid monomers and 
associated forms with high selectivity toward soluble β-amyloid oligomer, a potential 
biomarker in early diagnosis of Alzheimer’s disease. A detection limit of 5 pM was 
achieved, which indicated the high sensitivity of the newly developed ELISA test. 
2. A modular bottom-up approach was used to create foldameric protein–protein interaction 
inhibitor for separate hot spots. 
2.1.  A 256-membered foldamer library was designed and synthesized containing diverse 
surface patch mimetic 14-helix fragments. The affinity of the library members toward 
the model protein calmodulin with separate hot spots was tested in a pulldown assay, 
and hits having a high propensity to form a complex with the protein were determined. 
2.2.  Binding efficiencies of the four selected hits were quantified by two parallel 
experiments – ITC and fluorescence titration – and interactions were found in the low 
micromolar to submicromolar range. 
2.3. The best 12 fragments of the library were synthesized individually with free thiol 
functionality and a dynamic combinatorial library was generated in a glutathione redox 
buffer using calmodulin as template. Under this experimental condition, the best 
binding ligand was the thermodynamically most favored species, because the selection 
of the products is based on their position in the free energy landscape. Product 
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distribution of the 102-membered DCLs was analyzed and the most amplified dimeric 
helix considered to be the best ligand for calmodulin was selected for further 
characterization. 
2.4. The best ligand was re-synthesized via linking the fragments in appropiate orientation 
by the thioether linkage. It showed dissociation constants two orders of magnitude 
lower than those of the monomeric fragments. Competitive experiments confirmed 
that the foldameric ligand bound to the same binding site as the native ligand (C-
terminal of the vanilloid receptor) and the foldamer can function as a protein–protein 
interaction inhibitor. 
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